Literature DB >> 21194038

Whole body skeletal muscle transduction in neonatal dogs with AAV-9.

Yongping Yue1, Jin-Hong Shin, Dongsheng Duan.   

Abstract

Gene therapy of muscular dystrophy requires systemic gene delivery to all muscles in the body. Adeno-associated viral (AAV) vectors have been shown to lead to body-wide muscle transduction after a single intravascular injection. Proof-of-principle has been demonstrated in mouse models of Duchenne muscular dystrophy and limb girdle muscular dystrophy. Before initiating clinical trials, it is important to validate these promising results in large animal models. More than a dozen canine muscular dystrophy models have been developed. Here, we outline a protocol for performing systemic AAV gene transfer in neonatal dogs. Implementing this technique in dystrophic dogs will accelerate translational muscular dystrophy research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21194038      PMCID: PMC3118043          DOI: 10.1007/978-1-61737-982-6_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  22 in total

1.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

2.  Newborn screening for Duchenne muscular dystrophy: a psychosocial study.

Authors:  E P Parsons; A J Clarke; K Hood; E Lycett; D M Bradley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

3.  Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans.

Authors:  H Van Belle
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327

4.  Lack of homology between dog and human placental alkaline phosphatases.

Authors:  G Moak; H Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

5.  Crystal structure of alkaline phosphatase from human placenta at 1.8 A resolution. Implication for a substrate specificity.

Authors:  M H Le Du; T Stigbrand; M J Taussig; A Menez; E A Stura
Journal:  J Biol Chem       Date:  2000-12-20       Impact factor: 5.157

6.  Evolution of alkaline phosphatases in primates.

Authors:  D J Goldstein; C Rogers; H Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

7.  Canine X-linked muscular dystrophy: selective involvement of muscles in neonatal dogs.

Authors:  B A Valentine; B J Cooper
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

8.  Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency.

Authors:  Zhuping Xu; Yongping Yue; Yi Lai; Chaoyang Ye; Jianming Qiu; David J Pintel; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2004-09       Impact factor: 5.695

9.  The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy.

Authors:  Joe N Kornegay; Diane D Cundiff; Daniel J Bogan; Janet R Bogan; Carol S Okamura
Journal:  Neuromuscul Disord       Date:  2003-08       Impact factor: 4.296

10.  Rapid direct sequence analysis of the dystrophin gene.

Authors:  Kevin M Flanigan; Andrew von Niederhausern; Diane M Dunn; Jonathan Alder; Jerry R Mendell; Robert B Weiss
Journal:  Am J Hum Genet       Date:  2003-03-11       Impact factor: 11.025

View more
  18 in total

1.  Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

Authors:  Kleopatra Rapti; Vedell Louis-Jeune; Erik Kohlbrenner; Kiyotake Ishikawa; Dennis Ladage; Sergei Zolotukhin; Roger J Hajjar; Thomas Weber
Journal:  Mol Ther       Date:  2011-09-13       Impact factor: 11.454

2.  A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs.

Authors:  Jin-Hong Shin; Yongping Yue; Arun Srivastava; Bruce Smith; Yi Lai; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2011-12-14       Impact factor: 5.695

3.  Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs.

Authors:  Jin-Hong Shin; Yongping Yue; Bruce Smith; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2012-01-11       Impact factor: 5.695

4.  Duchenne muscular dystrophy gene therapy: Lost in translation?

Authors:  Dongsheng Duan
Journal:  Res Rep Biol       Date:  2011-03

5.  Full-length dystrophin reconstitution with adeno-associated viral vectors.

Authors:  William Lostal; Kasun Kodippili; Yongping Yue; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

6.  AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart.

Authors:  Xiufang Pan; Yongping Yue; Keqing Zhang; Chady H Hakim; Kasun Kodippili; Thomas McDonald; Dongsheng Duan
Journal:  Hum Gene Ther Methods       Date:  2015-04-01       Impact factor: 2.396

7.  Systemic Delivery of Adeno-Associated Viral Vectors in Mice and Dogs.

Authors:  Lakmini P Wasala; Chady H Hakim; Yongping Yue; N Nora Yang; Dongsheng Duan
Journal:  Methods Mol Biol       Date:  2019

8.  Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8.

Authors:  Xiufang Pan; Yongping Yue; Keqing Zhang; William Lostal; Jin-Hong Shin; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2013-05-09       Impact factor: 5.695

9.  Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.

Authors:  Yongping Yue; Xiufang Pan; Chady H Hakim; Kasun Kodippili; Keqing Zhang; Jin-Hong Shin; Hsiao T Yang; Thomas McDonald; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2015-08-11       Impact factor: 6.150

Review 10.  Gene therapy in monogenic congenital myopathies.

Authors:  Xuan Guan; Melissa A Goddard; David L Mack; Martin K Childers
Journal:  Methods       Date:  2015-10-14       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.